Benzinga | Jul 30, 2020 07:58AM EDT

AC Immune Announces It Is One Of The Winners Of Ken Griffin Alpha-Synuclein Imaging Competition From The Michael J. Fox Foundation For Parkinson's Research And Is Eligible To Receive $3.2M With Its Partner

AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition

The award follows compelling preclinical results presented at AAIC on the Company's alpha-synuclein positron emission tomography -(PET) tracer program

Further validates the ability of AC Immune's proprietary platforms to accelerate delivery of a new class of promising diagnostics in neurodegenerative diseases



LAUSANNE, Switzerland, July 30, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is one of the winners of the Ken Griffin Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation for Parkinson's Research (MJFF), and is eligible to receive together with its partner USD 3.2 million (CHF 3.1 million).

The funding will support the nonclinical and clinical investigation of AC Immune's proprietary alpha-synuclein-PET tracers, which are the most advanced in the field and could deliver the world's first imaging agent capable of accurately detecting and monitoring progression of Parkinson's disease (PD). The clinical arm of the AC Immune project will be conducted in partnership with Prof. Oskar Hansson's team of world-class researchers at Lund University and Sk?ne University Hospital in Sweden, which is a recognized Center of Excellence in the field of diagnostics for neurodegenerative diseases. Sk?ne University Hospital is eligible to receive USD 0.7 million over two years to support this arm of the project.